Propanc Biopharma Inc (PPCB)

PPCB...........................https://stockcharts.com/sc3/ui/?s=PPCB&p=w&b=5&g=0&id=p86431144783

Watching PPCB for $5.7 to $10.12

Share repurchase sends $PPCB price soaring on high volume. https://richardacavalli.wixsite.com/greenplanetmicrocaps/ppcb-exploding-volume

$PPCB: Share RePurchase plan sends it.... now $3

Nice moves............... almost 3bagger on the day here in PreMarket

GO $PPCB

*****************************************************

Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program
By Propanc Biopharma, Inc. | June 11, 2026, 8:30 AM

Share
PPCB
-2.17%
Propanc Biopharma Inc
Management Believes the Company is Entering a Transformative Stage with a Novel, First-In-Class Cancer Therapy for Treatment & Prevention of Metastatic Cancer from Solid Tumors

MELBOURNE, Australia, June 11, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced it has approved a share repurchase program authorizing the Company to repurchase up to $5.0 million of its common stock.

“With our recent advancements of the Company’s lead asset, PRP, towards entering the clinic with a novel, first-in-class cancer therapy to treat and prevent metastatic cancer from solid tumors with a pivotal Phase 1b, First-In-Human study in 30 to 40 advanced cancer patients, the management team believes we are entering a transformative stage for the Company. The work we’ve undertaken throughout this recent period, publishing key scientific data, filing patentable discoveries, forming partnerships with CRO’s, CDMO’s and suppliers, has us well positioned to advance PRP meaningfully and efficiently to achieve significant clinical milestones. This is further supported by US FDA Orphan Drug Designation for the treatment of pancreatic cancer which provides us with seven-year exclusivity in the market, post approval. The foundation is clearly there and as a result, we believe we are undervalued significantly,” said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. “Furthermore, this decision reflects our commitment to disciplined, flexible capital allocation. Repurchases will be considered when we believe the market price meaningfully understates intrinsic value and when buybacks compete favorably relative to other uses of capital. We believe we are approaching such a position. Importantly, when executed thoughtfully, buybacks allow continuing shareholders to increase their ownership in the Company's underlying assets, improve per share economics over time, and signal management's confidence in the long-term value of the business, while still preserving the financial flexibility needed to pursue attractive opportunities as they arise.”

Under the share repurchase program, the Company may buy back its common stock from time to time, in amounts, at prices, and at such times as the Company deems appropriate, subject to market conditions, pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, and federal and state laws governing such transactions, through a variety of methods, which may include open market purchases, privately negotiated transactions, block trades, accelerated share repurchase transactions, purchases through 10b5-1 trading plans, or by any combination of such methods. The repurchase program does not oblige the Company to acquire any specific number of shares and may be modified, discontinued, or suspended at any time.

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.

More information: www.propanc.com

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Company:
Propanc Biopharma, Inc.
James Nathanielsz

+61-3-9882-0780

info@propanc.com

Investor Contact:

irteam@propanc.com

Caesar has another Feast and you are paying for it.  And No you don’t get to eat during the Feast eveen though you are paying for it.Caesar in the end will Feast with another King and you will starve.There really should be a Law..Praying for Nathanielsz that he find Christ and do this properly by rewarding shareholders not milking them

PPCB has HUGE short interest and price is just to spike on a short squeeze

PPCB................................https://stockcharts.com/sc3/ui/?s=PPCB&p=w&b=5&g=0&id=p86431144783

All that is missing in this article is “we will reverse split you into oblivion!”

PPCB why it is reversing and going up now https://richardacavalli.wixsite.com/greenplanetmicrocaps/propanc-pancreatic-cancer

Buy signal https://richardacavalli.wixsite.com/greenplanetmicrocaps/propanc-pancreatic-cancer

Never an “if” with these clowns. Just a “when” is the next es

YET ANOTHER RS coming very soon,it was so announced last week.

1 for 30 just so they can remain on NASDAQ. What a SHAM.

"Execute a reverse stock split of the Company’s issued and outstanding shares of Common Stock at a ratio somewhere between one post-split share per ten pre-split shares (1:10) and one post-split share per thirty pre-split shares (1:30) (the “Reverse Stock Split”)."

How is this legal in any World?Simeone should go to jail… that will make the company investable if Caesar is removed feim the throne.

Nothing but talk…dilution machine!

Propanc Biopharma Spotlights PRP as Potential Breakthrough for Metastatic Solid TumorsMarch 3, 2026 10:34 AM
IH Market News
Propanc Biopharma (NASDAQ:PPCB) is drawing attention to the therapeutic promise of its lead candidate, PRP, an investigational proenzyme treatment aimed at tackling metastatic cancer arising from solid tumors—particularly aggressive, poorly differentiated forms associated with poor patient outcomes.Pancreatic cancer remains among the most lethal malignancies, with a five-year survival rate of just 13%, compared to an overall cancer survival rate near 70%. Despite incremental advances, existing therapies—including chemotherapy, targeted agents and newer treatment modalities—have delivered limited progress, often accompanied by significant toxicity and the development of drug resistance.PRP is designed to offer a differentiated approach. Administered intravenously, the therapy targets cancer stem cells, which are believed to drive tumor growth and recurrence. It also aims to inhibit metastasis by suppressing epithelial-mesenchymal transition (EMT), alter the tumor microenvironment, reduce angiogenesis and enhance tumor sensitivity to chemotherapy.According to preclinical findings, PRP demonstrated more than 85% inhibition of tumor growth in pancreatic cancer models. The company also reported reductions in fibrosis and markers of drug resistance, alongside a more favorable safety profile compared with conventional cytotoxic treatments. In a small compassionate-use study involving advanced-stage patients, survival reportedly increased from approximately 5.6 months to 9 months.



Differentiated Mechanism Versus Standard Therapies



Propanc positions PRP as a complementary strategy to existing cancer treatments:




Chemotherapy: PRP may improve responsiveness in resistant tumors, potentially enabling lower doses and reduced side effects.



Targeted therapies: Rather than focusing on single genetic mutations, PRP is designed to address cancer stem cells and metastatic spread more broadly.



Immunotherapy: By reshaping the tumor microenvironment, PRP may help convert immunologically “cold” pancreatic tumors into forms more responsive to immune-based treatments.




The company is preparing to initiate a Phase 1b First-In-Human clinical trial in 2026. The program is supported by recent capital raises, expanded intellectual property protection and Orphan Drug designation from the U.S. Food and Drug Administration for pancreatic cancer.With limited effective options currently available for metastatic pancreatic disease, Propanc believes PRP could represent a novel, lower-toxicity therapeutic avenue if clinical results validate its early promise.Propanc Biopharma stock price

Original: Propanc Biopharma Spotlights PRP as Potential Breakthrough for Metastatic Solid Tumors

PPCB................................a/h

PPCB...22...🥳...Nice Reversal Candle on the close...Feb 5,2026 News was interesting... https://finviz.com/news/301272/propanc-biopharma-unveils-prp-a-game-changing-proenzyme-therapy-poised-to-challenge-standard-cancer-treatments-in-the-3-billion-pancreatic-cancer-market

If they only knew you Nathanielsz.. they would keep their treasure..Law is based upon The Judgement 

This is a long term scam. Buyer beware. If they had anything of any value this would be $100/share. Preying on the pancreatic cancer that is rampant 

When Nathaliezs loses the Caesar Share which basically makes this a Private Company then and only then may this be an opportunity.I am just surprised no court or market has ended this fleecing of investors who own nothing.

I just report on RS's and this one was massive. So...just reporting the share pps after the RS about a year ago.

Did you not follow this scam f?  How does the government all street journal promote such investor theft?  It's embarrassing.  N xx thing they'll tell us it's safe for pregamamt wimen to take an experimental vaccine

This SCAM was $15 per share almost a year ago when they pulled that massive RS. That's exactly what RS's do,kill the share price forever.

After the huge reverse split that just happened, are they allowed to do that again?? I don't if there are rules to reverse splits. But this is already insane. I am in a bad way over this stock. I didn't look carefully. It's so clear now unfortunately. It's too late.

Nothing but dilution here soon rs en repeat process. Stay away

At with their PR about playing the crypto market today this POS tanked another 10% today. They "secured" $100M?? No doubt with some really bad toxic notes. Keep watching the OS and the Unrestricted shares.

News today and it says PPCB "Secures Up To $100M" .... I know Crypto has nothing to do with Cancer, but if the Enzyme treatment ever starts First in Human Trials PPCB will explode.

GLTA!


.

These clowns have DUMPED almost 13M shares since the RS early in 2025 and have bagged Millions of $$. Now they want to play Crypto market? Just where would that $100M come from? That has WHAT to do with a cancer cure?

Yeah...everyone knows the answer to that BS and that's why the stock has TANKED and will continue to do so.

I need help understanding; you posted a link below which shown AMAZING date from this company. On the flip side, everyone on this site says it's a scam company with 1 owner and nothing going on. I see the 1 owner, I've been on their site and see the potential. How could there be such a wide difference of opinion? I bought a chunk at $3.25, and I'm starting to think it will never get back up there to break even. I know that many biotech's are like this, and I jumper too quickly, but any thought would be appreciated. Thanks!

Farewell Propanc Bionothingness. My last post on this board...funymuny...out!

Just sold the one share I had left after these morons Reverse Split me into oblivion. So much for curing cancer...just a share printing scam! Buyer beware

Everything about ppcb sucks out loud. Beware of this dilution machine!

Just to clarify: PPCB has not "found" a way to buy $100 million in Ethereum, they plan to buy in the next 12 months $100 million..... Huge Difference!

I am still in and out of PPCB, I dont want to miss the runs that PPCB has once in a while!


.

Looks like PPCB found a way to buy $100 million in Etherium and use it for strategic deals AND to finance trials. Also looks like PPCB has cracked the cancer treatment code with their patented EMT modulators that have demonstrated in NIH clinical trial that it stops metastasis and allows the cancer cells to die a natural death. This could be far bigger than anyone realizes yet. https://www.allpennystocks.com/specialreportsus/3965/stopping-cancer-before-it-spreads-the-emt-revolution-in-oncology

PPCB now plans to buy $100 million in Ethereum in the next 12 months...... Wow, just Wow for that Caesar Share! What happened to the Enzyme treatment for cancer?

I do not have shares right now but it looks like I am going to miss another run, luckily I caught the last one though!


.

Wants to run on opm

Here we go again: Once completed, the goal is to submit a clinical trial application for the Phase 1, FIH study by the first half of 2026 at the Peter Mac Cancer Center, regarded as a leading cancer hospital in Australia, consistently ranking among the top 20 oncology centers globally, according to Oncology Republic. (bold emphasis mine) https://www.propanc.com/news-media/press-releases/detail/170/propanc-biopharma-provides-shareholder-update


Ive been reading the bold part for at least 6 years! Hopefully it finally happens!


.

ppcb acting like it wants to run. watching.

Tiny float, newly uplisted to Nasdaq, $4 million cash raise, groundbreaking new EMT modulator that has demonstrated new way to treat cancer effectively and with no adverse side effects, 67 million shares traded the first day, price was up as high as $9. This could be a huge runner right now.

I have been watching/investing in PPCB for years (ever since PPCH days)..... I bought in Friday again and sold some yesterday and the rest today. PPCB has its nice runs here and there but has always went back down (I finally caught one run). Now that PPCB is on Nasdaq it has more attention and more money flowing through it.

If the First in Human trials ever start and dilution stays at a minimum I think PPCB has a shot of actually sustaining their gains. PPCB just did an offering which raised almost $4 million so that will keep dilution to a minimum for the time being. If trials go well PPCB has the potential for massive price upside.

Their history on the OTC is bad, but hopefully this uplisting will change that. It was reverse split after reverse split on the OTC. I do expect to get back in and I am not sure at what PPS or when..... I will hold longer than a few days next time for sure.

GLTY!


.

Anyone looking at this stock today?

Why is it that some stocks go up when they create new shares which is dilution and others go down when they dilute? Nothing makes sense. Guess this is another trap that will crash today when all the club members sell. Remember if you are not in the club, you will always lose your $$$.

Almost the entire Outstanding Share count traded Pre-Market and PPCB is up almost 100%..... Im glad I got my little amount of shares Friday!

GLTY!


.

PPCB started trading on Nasdaq today! Im in for a few shares but dont expect much out of them right now.

I am confident we are getting closer to First in Human trails soon. Maybe all these years of PPCB saying "first half we expect to start" will finally happen!


.

Uplisted!

.

Looking promising here 🎅

They should delist this stick until Caesar share decommissioned.There is no equity,, it's a farce upon a farce

This all means nothing with a Caesar ShareNothingIt may be legalbut it's fraud in any true sense

Regardless you own monopoly sharesThey own nothingIf you do cart h a good pr you better cash out before ownwer does

Ask yourself How does the Board keep issuing shares, then reverse splitting the stock?  Or issuing more shares. ?Because the owner Nathanielsz has aubert Ed the Common Shre model by issuing himselfA Caesar Share!The Caesar Share has all the Voting and thus ownership rights!Caesar could sell his share for a billion dollars and leave common shares holding NOTHING!You could be right about the science, fund the entire company through succesful Trials and own Nothing.. Nothing